Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)
Status:
Completed
Trial end date:
2016-11-17
Target enrollment:
Participant gender:
Summary
Double-Blind Placebo-Controlled Randomized Phase 2 Study evaluating the efficacy of lirilumab
(IPH2102/BMS-986015) as Maintenance Treatment administered in elderly patients with Acute
Myeloid Leukemia (AML) in first complete remission